N4 Pharma CEO Nigel Theobald excited with siRNA programme (VIDEO)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss results for the year ended 31 December 2022.

Nigel explains how the market for N4 Pharma has changed in recent times, the findings from a strategic review of Nuvec as a delivery system, why the siRNA programme has taken greater prominence, the potential market for this programme and what investors can expect from N4 Pharma in 2023.

N4 Pharma Plc is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.

Find more news, interviews, share price & company profile here for:

    You can also listen to our interviews on: 

    Share this interview

    Want to share this interview on a forum? Use this forum friendly link: https://1lo.co/ya42x
    N4 Pharma CEO Nigel Theobald excited with siRNA programme (VIDEO)

    Other Interviews

    More News

    Ask your questions

    Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

    I have questions